Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitorsTommaso Clemente, Antonella Castagna, Laura Galli et al.|BMJ Open|2024Cited by 21
One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART StudyCamilla Muccini, Antonella Castagna, Nicola Gianotti et al.|Open Forum Infectious Diseases|2024Cited by 20
Inflammation burden score in multidrug-resistant HIV-1 infectionTommaso Clemente, Vincenzo Spagnuolo, Alessandra Bandera et al.|Journal of Infection|2023Cited by 8
Polypharmacy, anticholinergic burden and drug–drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registryMaria Mazzitelli, Laura Comi, Domenico Pontillo et al.|Journal of Antimicrobial Chemotherapy|2024Cited by 7
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO RegistryDaniele Armenia, Alessio Bellucci, Vincenzo Spagnuolo et al.|Journal of Antimicrobial Chemotherapy|2024Cited by 6